Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Podcasts|April 3, 2020
PsychPearls: The Coronavirus Anxiety Cycle
Author(s)Judson A. Brewer, MD, PhD
Sit back and listen to Dr Jud Brewer discuss integrative approaches to managing anxiety during the COVID-19 pandemic.
Advertisement
Dr Jud Brewer discusses integrative approaches to managing anxiety during the COVID-19 pandemic.
Dr Brewer is a neuroscientist and psychiatrist. He is Associate Professor in Behavioral and Social Sciences at Brown School of Public Health and Psychiatry and Director of Research and Innovation at the
His work has been featured on 60 Minutes, Time, NPR, and Psychiatric Times. Check out
Advertisement
Related to this article
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
New Adult ADHD Guidelines: What Resources Are Coming Soon
3
Brenipatide for Alcohol Use Disorder: Emerging Findings
4
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
5